In recent years, several glucagon-like peptide-1 (GLP-1)-based therapies for the treatment of type 2 diabetes mellitus (T2DM) have been developed. The aim of this work was to extend the semimechanistic integrated glucose-insulin model to include the effects of a GLP-1 analog on glucose homeostasis in T2DM patients. Data from two trials comparing the effect of steady-state liraglutide vs. placebo on the responses of postprandial glucose and insulin in T2DM patients were used for model development. The effect of liraglutide was incorporated in the model by including a stimulatory effect on insulin secretion. Furthermore, for one of the trials an inhibitory effect on glucose absorption was included to account for a delay in gastric emptying. A...
Aim: To gain further insights into the efficacy of SAR425899, a dual glucagon-like peptide-1/glucago...
Glucagon-like peptide-1 (GLP-1) is an incretinhormone physiologically playing a role in glucosehomeo...
Established therapies for type-2 diabetes effectively reduce blood glucose, but are often associated...
Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrien...
Diabetes is a group of metabolic diseases characterized by hyperglycaemia resulting from defects in ...
Glucagon-like polypeptide (GLP-1) receptor agonist treatment has multiple effects on glucose metabol...
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from vario...
Aims. Glucagon-like peptide-1 (GLP-1) analog promotes insulin secretion by acting on pancreatic β-ce...
Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrien...
GLP-1 analogues have been proven to be effective in the treatment of type 2 diabetes mellitus. They ...
Type 2 diabetes mellitus (T2DM) is progressive; the more intensively it is treated, the greater is t...
The complex pathophysiology of type 2 diabetes and its natural evolution, characterized by a progres...
Type 2 diabetes mellitus (T2DM) is a progressive disease associated with significant morbidity and m...
Combining insulin with glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (...
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of antidiabetic drugs devel...
Aim: To gain further insights into the efficacy of SAR425899, a dual glucagon-like peptide-1/glucago...
Glucagon-like peptide-1 (GLP-1) is an incretinhormone physiologically playing a role in glucosehomeo...
Established therapies for type-2 diabetes effectively reduce blood glucose, but are often associated...
Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrien...
Diabetes is a group of metabolic diseases characterized by hyperglycaemia resulting from defects in ...
Glucagon-like polypeptide (GLP-1) receptor agonist treatment has multiple effects on glucose metabol...
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from vario...
Aims. Glucagon-like peptide-1 (GLP-1) analog promotes insulin secretion by acting on pancreatic β-ce...
Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrien...
GLP-1 analogues have been proven to be effective in the treatment of type 2 diabetes mellitus. They ...
Type 2 diabetes mellitus (T2DM) is progressive; the more intensively it is treated, the greater is t...
The complex pathophysiology of type 2 diabetes and its natural evolution, characterized by a progres...
Type 2 diabetes mellitus (T2DM) is a progressive disease associated with significant morbidity and m...
Combining insulin with glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (...
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of antidiabetic drugs devel...
Aim: To gain further insights into the efficacy of SAR425899, a dual glucagon-like peptide-1/glucago...
Glucagon-like peptide-1 (GLP-1) is an incretinhormone physiologically playing a role in glucosehomeo...
Established therapies for type-2 diabetes effectively reduce blood glucose, but are often associated...